Novavax Statistics

Total Valuation

Novavax has a market cap or net worth of $1.29 billion. The enterprise value is $833.42 million.

Market Cap	1.29B
Enterprise Value	833.42M

Important Dates

The next estimated earnings date is Friday, May 8, 2026, before market open.

Earnings Date	May 8, 2026
Ex-Dividend Date	n/a

Share Statistics

Novavax has 162.94 million shares outstanding. The number of shares has increased by 13.74% in one year.

Current Share Class	162.94M
Shares Outstanding	162.94M
Shares Change (YoY)	+13.74%
Shares Change (QoQ)	+1.74%
Owned by Insiders (%)	0.69%
Owned by Institutions (%)	58.96%
Float	140.22M

Valuation Ratios

The trailing PE ratio is 3.08.

PE Ratio	3.08
Forward PE	n/a
PS Ratio	1.15
Forward PS	2.89
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	1.89
EV / Sales	0.74
EV / EBITDA	1.41
EV / EBIT	1.48
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.13

Current Ratio	2.13
Quick Ratio	1.83
Debt / Equity	n/a
Debt / EBITDA	0.46
Debt / FCF	n/a
Interest Coverage	24.98

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	25.72%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	78.60%
Weighted Average Cost of Capital (WACC)	16.91%
Revenue Per Employee	$1.50M
Profits Per Employee	$587,853
Employee Count	749
Asset Turnover	0.82
Inventory Turnover	40.39

Taxes

In the past 12 months, Novavax has paid $1.87 million in taxes.

Income Tax	1.87M
Effective Tax Rate	0.42%

Stock Price Statistics

The stock price has increased by +18.74% in the last 52 weeks. The beta is 2.65, so Novavax's price volatility has been higher than the market average.

Beta (5Y)	2.65
52-Week Price Change	+18.74%
50-Day Moving Average	9.14
200-Day Moving Average	8.18
Relative Strength Index (RSI)	38.41
Average Volume (20 Days)	3,131,254

Short Selling Information

The latest short interest is 46.34 million, so 28.44% of the outstanding shares have been sold short.

Short Interest	46.34M
Short Previous Month	44.99M
Short % of Shares Out	28.44%
Short % of Float	33.05%
Short Ratio (days to cover)	12.37

Income Statement

In the last 12 months, Novavax had revenue of $1.12 billion and earned $440.30 million in profits. Earnings per share was $2.58.

Revenue	1.12B
Gross Profit	713.62M
Operating Income	563.24M
Pretax Income	442.17M
Net Income	440.30M
EBITDA	590.85M
EBIT	563.24M
Earnings Per Share (EPS)	$2.58

Full Income Statement

Balance Sheet

The company has $735.08 million in cash and $278.05 million in debt, giving a net cash position of $457.04 million or $2.81 per share.

Cash & Cash Equivalents	735.08M
Total Debt	278.05M
Net Cash	457.04M
Net Cash Per Share	$2.81
Equity (Book Value)	-127.75M
Book Value Per Share	-0.79
Working Capital	518.33M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$244.64 million and capital expenditures -$5.56 million, giving a free cash flow of -$250.20 million.

Operating Cash Flow	-244.64M
Capital Expenditures	-5.56M
Depreciation & Amortization	27.61M
Net Borrowing	32.54M
Free Cash Flow	-250.20M
FCF Per Share	-$1.54

Full Cash Flow Statement

Margins

Gross margin is 63.52%, with operating and profit margins of 50.13% and 39.19%.

Gross Margin	63.52%
Operating Margin	50.13%
Pretax Margin	39.36%
Profit Margin	39.19%
EBITDA Margin	52.59%
EBIT Margin	50.13%
FCF Margin	n/a

Dividends & Yields

Novavax does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-13.74%
Shareholder Yield	-13.74%
Earnings Yield	34.12%
FCF Yield	-19.39%

Analyst Forecast

The average price target for Novavax is $11.33, which is 43.06% higher than the current price. The consensus rating is "Hold".

Price Target	$11.33
Price Target Difference	43.06%
Analyst Consensus	Hold
Analyst Count	9
Revenue Growth Forecast (5Y)	-0.48%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on May 10, 2019. It was a reverse split with a ratio of 1:20.

Last Split Date	May 10, 2019
Split Type	Reverse
Split Ratio	1:20

Scores

Novavax has an Altman Z-Score of -1.81 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.81
Piotroski F-Score	5